252 related articles for article (PubMed ID: 27793034)
21. Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
Subbiah V; Kuravi S; Ganguly S; Welch DR; Vivian CJ; Mushtaq MU; Hegde A; Iyer S; Behrang A; Ali SM; Madison RW; Venstrom JM; Jensen RA; McGuirk JP; Amin HM; Balusu R
ESMO Open; 2021 Aug; 6(4):100172. PubMed ID: 34242968
[TBL] [Abstract][Full Text] [Related]
22. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.
Tsuyama N; Sakamoto K; Sakata S; Dobashi A; Takeuchi K
J Clin Exp Hematop; 2017; 57(3):120-142. PubMed ID: 29279550
[TBL] [Abstract][Full Text] [Related]
23. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
[TBL] [Abstract][Full Text] [Related]
24. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
[TBL] [Abstract][Full Text] [Related]
25. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
26. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
27. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.
Singh RR; Cho-Vega JH; Davuluri Y; Ma S; Kasbidi F; Milito C; Lennon PA; Drakos E; Medeiros LJ; Luthra R; Vega F
Cancer Res; 2009 Mar; 69(6):2550-8. PubMed ID: 19244133
[TBL] [Abstract][Full Text] [Related]
28. KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth.
Hwang J; Song I; Lee K; Kim HR; Hong EH; Hwang JS; Ahn SH; Lee J
Invest New Drugs; 2020 Oct; 38(5):1282-1291. PubMed ID: 31956933
[TBL] [Abstract][Full Text] [Related]
29. Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells.
Kuravi S; Cheng J; Fangman G; Polireddy K; McCormick S; Lin TL; Singh AK; Abhyankar S; Ganguly S; Welch DR; Jensen RA; McGuirk JP; Balusu R
Mol Cancer Res; 2021 May; 19(5):913-920. PubMed ID: 33514657
[TBL] [Abstract][Full Text] [Related]
30. ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.
Martinengo C; Poggio T; Menotti M; Scalzo MS; Mastini C; Ambrogio C; Pellegrino E; Riera L; Piva R; Ribatti D; Pastorino F; Perri P; Ponzoni M; Wang Q; Voena C; Chiarle R
Cancer Res; 2014 Nov; 74(21):6094-106. PubMed ID: 25193384
[TBL] [Abstract][Full Text] [Related]
31. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.
Parrilla Castellar ER; Jaffe ES; Said JW; Swerdlow SH; Ketterling RP; Knudson RA; Sidhu JS; Hsi ED; Karikehalli S; Jiang L; Vasmatzis G; Gibson SE; Ondrejka S; Nicolae A; Grogg KL; Allmer C; Ristow KM; Wilson WH; Macon WR; Law ME; Cerhan JR; Habermann TM; Ansell SM; Dogan A; Maurer MJ; Feldman AL
Blood; 2014 Aug; 124(9):1473-80. PubMed ID: 24894770
[TBL] [Abstract][Full Text] [Related]
32. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
33. EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.
Schmidt J; Bonzheim I; Steinhilber J; Montes-Mojarro IA; Ortiz-Hidalgo C; Klapper W; Fend F; Quintanilla-Martínez L
Lab Invest; 2017 Sep; 97(9):1095-1102. PubMed ID: 28581487
[TBL] [Abstract][Full Text] [Related]
34. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
Staber PB; Vesely P; Haq N; Ott RG; Funato K; Bambach I; Fuchs C; Schauer S; Linkesch W; Hrzenjak A; Dirks WG; Sexl V; Bergler H; Kadin ME; Sternberg DW; Kenner L; Hoefler G
Blood; 2007 Nov; 110(9):3374-83. PubMed ID: 17690253
[TBL] [Abstract][Full Text] [Related]
35. Genetics of anaplastic large cell lymphoma.
Zeng Y; Feldman AL
Leuk Lymphoma; 2016; 57(1):21-7. PubMed ID: 26104084
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.
Karaca Atabay E; Mecca C; Wang Q; Ambrogio C; Mota I; Prokoph N; Mura G; Martinengo C; Patrucco E; Leonardi G; Hossa J; Pich A; Mologni L; Gambacorti-Passerini C; Brugières L; Geoerger B; Turner SD; Voena C; Cheong TC; Chiarle R
Blood; 2022 Feb; 139(5):717-731. PubMed ID: 34657149
[TBL] [Abstract][Full Text] [Related]
37. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.
Prokoph N; Probst NA; Lee LC; Monahan JM; Matthews JD; Liang HC; Bahnsen K; Montes-Mojarro IA; Karaca-Atabay E; Sharma GG; Malik V; Larose H; Forde SD; Ducray SP; Lobello C; Wang Q; Luan SL; Pospíšilová Š; Gambacorti-Passerini C; Burke GAA; Pervez S; Attarbaschi A; Janíková A; Pacquement H; Landman-Parker J; Lambilliotte A; Schleiermacher G; Klapper W; Jauch R; Woessmann W; Vassal G; Kenner L; Merkel O; Mologni L; Chiarle R; Brugières L; Geoerger B; Barbieri I; Turner SD
Blood; 2020 Oct; 136(14):1657-1669. PubMed ID: 32573700
[TBL] [Abstract][Full Text] [Related]
38. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
Shi P; Lai R; Lin Q; Iqbal AS; Young LC; Kwak LW; Ford RJ; Amin HM
Blood; 2009 Jul; 114(2):360-70. PubMed ID: 19423729
[TBL] [Abstract][Full Text] [Related]
39. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
40. Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.
Tabbò F; Ponzoni M; Rabadan R; Bertoni F; Inghirami G;
Curr Opin Hematol; 2013 Jul; 20(4):374-81. PubMed ID: 23673339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
